Assignee
PHARMA CINQ LLC
US·4 granted patents·7 pending applications·0 citations·filing 2019–2025
Top patents by PatentIndex Score
11 records- 0182US2024374683A1Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptidePHARMA CINQ LLC·Filed 2024·Application pending·0 cites
- 0281US2025034139A1Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activityPHARMA CINQ LLC·Filed 2024·Application pending·0 cites
- 0376US2024310386A1Antibodies and methods for the detection of cell deathPHARMA CINQ LLC·Filed 2023·Application pending·0 cites
- 0471US12076367B2Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptidePHARMA CINQ LLC·Filed 2021·Granted Sep 3, 2024·0 cites·10 claims
- 0570US12139483B2Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activityPHARMA CINQ LLC·Filed 2021·Granted Nov 12, 2024·0 cites·19 claims
- 0669US2024342313A1Vector encoding rod-derived cone viability factor and human igk signal sequencePHARMA CINQ LLC·Filed 2024·Application pending·0 cites
- 0764US2026091133A1Rod-derived cone viability factor fusion proteinPHARMA CINQ LLC·Filed 2025·Application pending·0 cites
- 0857US12577270B22′,3′-diacetyluridine substituted with acetoacetyl at the 5′ positionPHARMA CINQ LLC·Filed 2021·Granted Mar 17, 2026·0 cites·29 claims
- 0957US2024299434A1Uridine triacetate amorphous formulationPHARMA CINQ LLC·Filed 2022·Application pending·0 cites
- 1049US2024158431A1Compositions and compounds for co-delivery of uridine and ketoleucinePHARMA CINQ LLC·Filed 2022·Application pending·0 cites
- 1144US12558368B2Compositions and devices for systemic delivery of uridinePHARMA CINQ LLC·Filed 2019·Granted Feb 24, 2026·0 cites·12 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →